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Endometrial cancer (EC) incidence rates vary ~10-fold worldwide, in part due to variation in EC risk factor profiles. Using an EC
risk model previously developed in the European EPIC cohort, we evaluated the prevention potential of modified EC risk factor
patterns and whether differences in EC incidence between a European population and low-risk countries can be explained by
differences in these patterns. Predicted EC incidence rates were estimated over 10 years of follow-up for the cohort before and
after modifying risk factor profiles. Risk factors considered were: body mass index (BMI, kg/m2), use of postmenopausal
hormone therapy (HT) and oral contraceptives (OC) (potentially modifiable); and, parity, ages at first birth, menarche and
menopause (environmentally conditioned, but not readily modifiable). Modeled alterations in BMI (to all ≤23 kg/m2) and HT
use (to all non-HT users) profiles resulted in a 30% reduction in predicted EC incidence rates; individually, longer duration of
OC use (to all ≥10 years) resulted in a 42.5% reduction. Modeled changes in not readily modifiable exposures (i.e., those not
contributing to prevention potential) resulted in ≤24.6% reduction in predicted EC incidence. Women in the lowest decile of a
risk score based on the evaluated exposures had risk similar to a low risk countries; however, this was driven by relatively
long use of OCs (median = 23 years). Our findings support avoidance of overweight BMI and of HT use as prevention strategies
for EC in a European population; OC use must be considered in the context of benefits and risks.
What’s new?
Endometrial cancer rates vary considerably around the world, with incidence rates higher in Europe and North America than in parts
of Asia and Africa. Here, the authors investigated how much of the risk disparity arises from modifiable factors, and how much
modifying these factors could reduce cancer incidence. The 10% of European women with lowest risk had similar incidence to
women in low-risk countries, they found. Their model predicted that in European women, maintaining BMI below 23 kg/m2 and
avoiding postmenopausal hormone use could reduce risk by 30%. Long-term use of oral contraceptives could reduce risk by 42.5%.
Introduction
Endometrial cancer (EC) incidence rates show wide variation
worldwide, with estimated age-standardized rates (ASR; standard-
ized to World Health Organization (WHO) World Standard Pop-
ulation) of 15 per 100,000 women and higher in 2018 in Europe
and North America but much lower rates reported by relatively
high-quality cancer registries in parts of Africa and Asia, for exam-
ple, in Algeria (ASR = 2.2/100,000) or India (ASR = 1.9/100,000).1
For the most part, this variation may be caused by differences in
the prevalence of nongenetic and thus theoretically modifiable risk
factors. Established risk factors for EC include older age, over-
weight and obesity, nulliparity/low parity, a relatively young age at
last full-term pregnancy, and having experienced a relatively early
menarche and/or latemenopause, reflecting a larger lifetime cumu-
lative number of ovulatory menstrual cycles.2 In addition, the use
of postmenopausal hormone therapy (HT) can either increase or
decrease risk, depending on both on its composition (estrogen-
only, or estrogen-plus-progestin combinations)3 and a woman’s
degree of adiposity (i.e., high body mass index [BMI]).4 Finally,
long-term use of oral contraceptives (OC) is associated with
marked reductions in EC risk, which persist for years after cessa-
tion of use,5 and smoking has also been associated with lower risk.2
Based on these established risk (and protective) factors, we pre-
viously derived a statistical model to predict a woman’s absolute
EC risk, in view of identifying high-risk women who may benefit
from targeted prevention measures (risk stratification), using data
from the European Prospective Investigation into Cancer and
Nutrition (EPIC) cohort.6 Here, we extend our analyses, applying
this previously derived risk model to the EPIC data to (i) estimate
the theoretical potential for the prevention of EC in Western
Europe, or in similar higher-risk populations, through risk factor
avoidance or alterations in exposure patterns, and (ii) evaluate the
extent to which the higher EC risk in the European population, as
compared to a low-risk country such as India, can be explained by
the prevalence of exposure to primary risk factors.
Methods
EPIC cohort
The EPIC cohort was established between 1992 and 2000 at
23 centers in 10 countries: Denmark, France, Germany, Greece,
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Italy, the Netherlands, Norway, Spain, Sweden and the United
Kingdom. Details of the study design have been published previ-
ously.7,8 Briefly, more than 500,000 men and women mostly
between the ages of 35–75 years of age were enrolled; partici-
pants provided detailed information on diet and lifestyle, includ-
ing data on reproductive and menstrual history, hormone use
and medical history. In all countries except France, Germany
and Greece and the center of Naples, Italy, the prospective ascer-
tainment of incident cancer cases was based on record linkage to
cancer registries, whereas in France, Germany, Greece and
Naples, Italy, a combination of active follow-up with participants
and their next-of-kin, and outcome verification with medical and
health insurance records was used. In all countries, vital status
was available from mortality registries. End of follow-up for can-
cer outcomes and mortality for France, Germany, Greece and
Naples, Italy, was the earliest of date of last contact, cancer diag-
nosis or death (2008–2013). For the remaining study centers
included in our study, end of follow-up ranged from 2009
(Varese and Murcia, Spain) to 2013 (San Sebastian and Asturias,
Spain and Turin, Italy and Greece). Participants from Norway
and Sweden were excluded due to missing data on key parame-
ters. Ethical approval for the EPIC study was obtained from the
International Agency for Research on Cancer (IARC) ethics
committee, and the ethics committees of the participating cen-
ters. Participants provided informed consent.
Statistical model
The analyses for this article are based on the EC risk prediction
model we developed previously within EPIC.6 Briefly, this model
estimates absolute risk of EC through combining a relative risk
score from individual risk factor information RR(x) with age-
specific piecewise constant baseline risk, and additionally correcting
for competing risk of hysterectomy or death. All age-specific risk
components are adjusted for country. The relative risk score
RR(x) incorporates data on bodymass index (BMI [kg/m2], contin-
uous), age at menarche (per year, continuous), duration of OC use,
OC use and BMI interaction (ever OC use by BMI categories; <25,
25 to <30, 30+), parity (nulliparous, 1,2,3+), age at first term
pregnancy (continuous), menopausal status at recruitment (pre-,
peri-, postmenopausal), age at menopause (per year, continuous,
centered at age 50), duration of postmenopausal HT use (per year,
continuous), and a smoking status and menopausal status interac-
tion (current or former smoker by menopausal status: pre-, peri-,
postmenopausal), and is defined as the following:
RR = exp 0:030×BMI – 0:023× age at 1st period – 13ð Þ½
– 0:019 if leanOC−userð Þ – 0:013 if overweightOC−userð Þ
– 0:036 if obeseOC−userð Þ – 0:023× duration of OC
−use in yearsð Þ – 0:051 if single parousð Þ
– 0:10 if 2 full− term pregnanciesð Þ
– 0:22 if 3 or more full− term pregnanciesð Þ
– 0:017× age at 1st full− term pregnancy – 24ð Þ
– 0:088 if peri−menopausalð Þ
– 0:20 if postmenopausalð Þ+ 0:029× age atmenopause – 50ð Þ
+ 0:031× duration of HT−use in yearsð Þ
– 0:11 if premenopausal former smokerð Þ
+ 0:040 if premenopausal current smokerð Þ
– 0:12 if postmenopausal former smokerð Þ
– 0:21 if postmenopausal current smokerð Þ
– 0:14 if peri−menopausal former smokerð Þ ð1Þ
A more detailed description of model development and
validation is given in our previous publication.6
Analytic cohort and exclusions
Ten-year risk was evaluated in our study. The analytic cohort
included all women who were either diagnosed with EC within
the first 10 years of follow-up, were diagnosed with a different
cancer or died during that time, or who were followed for at least
10 years (n = 17,467 with <10 years follow-up excluded). Women
reporting hysterectomy or prevalent cancer (except non-
melanoma skin cancer) at baseline or with no follow-up data were
excluded (n = 65,808). To avoid bias from extreme risk estimates
for BMI in the current analysis, all women with height <130 cm
(n = 15) and women with a BMI above 50 (n = 108) were
excluded from our analyses. Missing values in parity (4.8%), age
at first term pregnancy (0.5%), number of children (8.2%), pill
use and duration of pill use (3.2%; 14.0%), HT use and duration
of HT use (7.1%; 24.3%), and smoking status (2.7%) were fivefold
imputed with multiple chained-equation imputation using the
R-package “mice”.9,10 Data on country, study center, BMI, age at
recruitment, menopausal status and incident diagnosis of EC were
included in the imputation models. As the risk model was origi-
nally fitted for women within the age range of 40–70 years at
recruitment, risk estimates were not calculated for women youn-
ger than 40 years (n = 34,666) or older than 70 years (n = 4,630).
The data set for analysis included a total of 192,089 women.
Model calibration in the analytic cohort
Given that the analytic cohort included in our study was not
identical to that included in the model development, we evalu-
ated calibration of the model by calculating the ratio of expected
to observed cases and with a calibration plot of observed versus
expected by decile of predicted risk.
Estimation of prevention potential
To estimate the theoretical potential for EC prevention, the risk
model was used to calculate predicted 10-year incidence rates
within the cohort, with risk factors as originally observed (refer-
ence level), or under theoretical scenarios of truncated risk factor
distributions, where women’s exposures were truncated at theo-
retically feasible low-risk levels, assigning the limit value
(i.e., truncation point) for the low-risk category to all women
who had observed values outside the low-risk range (e.g., in ana-
lyses of BMI, where 23 kg/m2 was defined as the truncation
point, all women with BMI > 23 kg/m2 were assigned a value of
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BMI = 23 kg/m2). BMI was also modeled with all women with
BMI > 25 kg/m2 with a 2.5 kg/m2 reduction in BMI (e.g., a
6.5 kg weight loss in a 1.61 m tall woman [corresponding to
average height in EPIC]). Predicted incidence rates on the basis
of these modified, hypothetical risk profiles were calculated for
risk factors individually and in combination, and were examined
for subsets of factors considered potentially modifiable (BMI,
OC use, HT use), or not readily modifiable (ages at menarche
and menopause, number of term pregnancies, age at first preg-
nancy) for prevention purposes.
To explore risk contours for combinations of EC risk fac-
tors, we used the relative risk model component (1) described
above and defined deciles of the relative risk score using sub-
sets of the risk factors included in the risk model: (i) BMI, OC
use, HT use, parity, age at first birth and ages at menarche
and menopause (full risk model excluding smoking); (ii) BMI,
OC use, HT use (modifiable components of the risk model).
We further evaluated deciles of the risk score using these sub-
sets of variables, but excluding OC use given that while OC
use is modifiable, it must be considered in a broader context
of risks and benefits. Using the complete absolute risk model
and the women’s observed risk factor combinations we esti-
mated incidence rates (i.e., predicted cases per 100,000
person-years of follow-up) for women in the lowest deciles of
risk based on the previously defined sets of risk factors.
For comparability with EC incidence rates reported in
Globocan1 we calculated age-specific rates, overall and for lower-
risk profiles, for women in the EPIC cohort in 5-year age catego-
ries. The age-specific rates were calculated as a sum of women’s
predicted EC risk contributions to up to three successive 5-year
age categories, weighted by the observation times (person-years)
that women spent in each 5-year age category during their
cumulative follow-up time of up to 10 years. We further used
incidence rates for Chennai, India, between 1994 and 2008
(corresponding to the years of follow-up in the EPIC cohort) as
a representative example of incidence rates in India, a country
with low incidence rates and high-quality data from cancer regis-
tries, as age-specific incidence rates were not available for India
as a whole in Globocan 2018. Summary data for India, Europe
(EU28 index), and for countries classified as having low human
development index (HDI) as reported in Globocan 201211 were
evaluated in a secondary analysis (age-specific incidence rates for
these populations not available in Globocan 2018).
All statistical analyses were conducted with SAS 9.4 and
with R (version 3.3.1, package “mice”).9,10
Data availability
Data are available by application to the EPIC Steering Com-
mittee (https://epic.iarc.fr/access/).
Results
Baseline characteristics of the study population are provided
in Table 1. The median age at recruitment was 52.5 years
(95% range, 41–67), and median BMI was 24.3 kg/m2
(95% range, 18.8–36.2). At baseline, 30% of women were
premenopausal, 57% had reported ever use of OCs (median
duration: 5 years), and 25% had reported ever use of HT
(median duration: 2 years). A total of 85% of women were
parous, with 34% of women reporting 3 or more children.
Table 1. Distribution of endometrial cancer risk factors in the analytic
cohort: EPIC cohort (n = 192,089)
Characteristic
n (%) or Median (95%
range)
Noncases 191,253 (100%)
Incident endometrial case in first 5 years of follow-up
Observed 836 (0%)
Predicted 832 (0%)
10-year risk of EC (Median
[min–max])
0.0031 (0.000; 0.186)
n (%)/Median (95%-range)
Age at recruitment 52.5 (41.1; 67.0)
Country of residence
Denmark 24,898 (13%)
France 56,206 (29%)
Germany 12,826 (7%)
Greece 8,361 (4%)
Italy 24,874 (13%)
The Netherlands 17,679 (9%)
Spain 18,224 (9%)
United Kingdom 29,021 (15%)
Height (cm) 161 (149–174)
Weight (kg) 63.6 (47.5–93.1)
BMI (kg/m2) 24.3 (18.8–36.2)
Age at menarche 13 (10–16)
OC use, ever 109,196 (57%)
Duration of OC use (years) 5 (1–25)
Ever full-term pregnancy 164,152 (85%)
One child1 28,872 (18%)
Two children1 79,775 (49%)
Three or more1 55,506 (34%)
Age at first full term pregnancy,
years1
25 (18–35)
Premenopausal 56,682 (30%)
Perimenopausal 33,970 (18%)
Postmenopausal 101,437 (53%)
Age at menopause, years2 50 (40–57)
HT use, ever2 47,816 (25%)
Duration of HT use, years3 2.00 (0.17; 15.34)
Smoking at recruitment
Current smoker 32,880 (17%)
Former smoker 42,732 (22%)
Never smoker 116,477 (61%)
1Among parous women.
2Among women postmenopausal at recruitment.
3Among ever HT users.
Abbreviations: EC, endometrial cancer, BMI, Body mass index, OC, oral
contraceptive, HT, hormone therapy.
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The median age at menarche was 13 years (95% range, 10–16)
and median age at menopause was 50 (95% range, 40–57).
Baseline characteristics of participants by country are pro-
vided in Supporting Information Table S1.
Among the 192,089 women included in the analytic
cohort, 836 were diagnosed with EC in the first 10 years of
follow-up. With risk factor profiles as observed, the risk model
predicted a total of 832 incident ECs within the first 10 years,
corresponding to a ratio of expected to observed cases of 1.0
(95% confidence interval, 0.93–1.06) and a predicted overall
incidence rate in EPIC of 43.3/100,000 person-years (py) of
follow-up (ASR: 11.4 per 100,000 years). A plot of observed
versus predicted risk of EC by decile of predicted risk further
documents the excellent model calibration, with observed ver-
sus predicted values on a straight line with slope 1.0 and zero
intercept (Supporting Information Fig. S1).
We first evaluated predicted overall incidence rates for the
EPIC cohort under hypothetical changes in potentially modifi-
able risk factors, individually and in combination (Table 2).
Modeling BMI as maximally 23 kg/m2 or all participants with
never HT use led to reductions in predicted incidence rates
ranging from 10.3% (HT use, predicted incidence rate:
38.9/100,000 py) to 21.9% (BMI, predicted incidence rate
33.8/100,000 py), as compared to the cohort with risk profiles
as observed; observed prevalence of BMI ≤23 kg/m2 and never
HT use was 36% and 75%, respectively. BMI modeled with a
2.5 kg/m2 reduction for women with BMI > 25 kg/m2 resulted
in a more modest 8.8% reduction in predicted incidence rates
(to 39.5/100,000). Modeling BMI as maximally 23 kg/m2 and
all participants as never HT users resulted in a 30.4% reduc-
tion in the predicted incidence rate (30.2/100,000 py; observed
prevalence of both BMI ≤23 kg/m2 and never HT use = 27%).
Assigning a minimum duration of 10 years of OC use to all
women resulted in a 42.5% reduction in the predicted inci-
dence rate (to 24.9/100,000 py; observed prevalence = 19%),
whereas minimum duration of OC use of 20 years reduced
the predicted incidence rate by 67.2% (to 14.2/100,000
person-years; observed prevalence = 8%). In combination,
considering the three potentially modifiable factors together
and modeling BMI≤23 kg/m2, OC use for ≥20 years, and
never use of HT for all women, the predicted incidence rate
was reduced by 75.7% (to 10.5/100,000 person-years); this
combination of exposure levels, however, was observed for
only 2% of the EPIC participants.
Table 2. Predicted reduction in crude endometrial cancer incidence rates through modification of risk factor profiles: EPIC cohort (n = 192,089)
Observed prevalence of target
risk profile Cases (n)
Crude incidence rate
(relative difference %)1
Observed cases over 10 years of follow-up 836 43.5
Projected cases over 10 years 832 43.3 (ref)
Estimated predicted case numbers and incidence rates given modeled risk factor distributions
Modeling changes in BMI and HT use
BMIà ≤23 kg/m2 36% 650 33.8 (−21.9%)
BMI > 25à −2.5 kg/m2 n/a 758 39.5 (−8.8%)
HT useà never 75% 746 38.9 (−10.3%)
BMIà ≤23 kg/m2, HT useà never 27% 580 30.2 (−30.4%)
Modeling changes in OC use, alone or in combination with other risk factors
OC useà ≥10 years 19% 478 24.9 (−42.5%)
OC useà ≥10 years, BMIà ≤23 kg/m2, HT useà
never
6% 355 18.5 (−57.3%)
OC useà ≥20 years 8% 273 14.2 (−67.2%)
OC useà ≥20 years, BMIà ≤23 kg/m2, HT useà
never
2% 202 10.5 (−75.7%)
Modeling changes menstrual and reproductive history
Age at menarcheà ≥13 years 61% 803 41.8 (−3.5%)
Age at menopauseà ≤48 years 14% 741 38.6 (−11.0%)
Age 1st FTPà ≥25 years 43% 784 40.8 (−5.8%)
Number of childrenà ≥3 29% 628 32.7 (−24.6%)
Modeling changes in combinations of risk factors, other than OC
BMIà ≤23 kg/m2, HT useà never, menarcheà
≥13 years, allà ≥3 children
4% 420 21.8 (−49.6%)
BMIà ≤23 kg/m2, HT useà never, menarcheà
≥13 years, allà≥3 children, age 1st FTPà
≥25 years, age at menopauseà ≤48 years
0.2% 350 18.2 (−57.9%)
1Cases per 100,000 person-years over 10 years of follow-up.
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We next evaluated risk factors influenced by physical
and/or cultural environments, but not readily modifiable to
quantify predicted reductions in EC incidence associated with
differences in the prevalence of these risk factors. The risk
model predicted moderate (−3.5 to −11.0%) reductions in the
EC incidence rate when we modeled all EPIC women as hav-
ing age at menarche ≥13 years, a first child at age ≥25 years
or age at menopause ≤48 years (reported prevalence of these
exposure levels ranged from 14% [age at menopause] to 61%
[age at menarche]). Our analyses predicted a more substantial
reduction (−24.6%; to 32.7/100,000 py) in the EC incidence
rate when all women were modeled as having 3 or more chil-
dren (reported by 29% of participants). The combination of
low BMI (≤ 23 kg/m2), never use of HT, late menarche
(age ≥ 13 years) and higher parity (≥3 children), a combina-
tion reported by 4% of the women in EPIC, was associated
with a 49.6% reduction in the incidence rate (to 21.8/100,000
person-years). Results were similar when the ASRs were com-
pared, rather than the crude predicted incidence rates
(Supporting Information Table S2).
Finally, we evaluated predicted incidence rates by deciles of
our relative risk score, to compare these predicted rates to
those reported in Globocan, specifically for lower-risk coun-
tries. We evaluated risk profiles using the multivariable
relative risk component of our model. Risk profiles were
defined based on the following sets of variables: (i) BMI, HT
use, parity, age at 1st birth, and ages at menarche and meno-
pause (full risk model excluding smoking); and (ii) BMI, OC
use, HT use (modifiable components of the risk model). These
scores were further defined with the variables stated previ-
ously (i.e., in (i) and (ii) above) but excluding OC use.
Women in the lowest decile of the relative risk score based on
all variables (except smoking) had lower BMI (median
22.8 kg/m2), and a higher proportion were postmenopausal
(68%), parous (93%; 41% with 3+ children), and reported ever
use of OCs (94%; median duration 23 years), relative to the
cohort overall (Supporting Information Table S3). When the
scores were derived excluding OC use, ever use of OCs and
OC use duration in the lowest decile were more similar to the
overall cohort than for relative risk scores including OC use
(e.g., score based on all factors except smoking and OC use,
ever OC use = 47% (full cohort 57%) and duration = 5 years
(full cohort = 5 years); variable distributions in lowest deciles
of all presented relative risk scores are shown in Supporting
Information Table S3).
Figure 1 shows the age-specific incidence rates predicted
within EPIC overall, and for women in the lowest decile of
the multivariable risk scores, and for India (Chennai cancer
Figure 1. Endometrial cancer incidence, per 100,000 person years and within 5-year categories of age, predicted in EPIC over a 10-year
follow-up overall and for women with observed low-risk profiles and comparison with incidence rates in India. [Color figure can be viewed at
wileyonlinelibrary.com]
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registry) as a representative “low risk” area. For women in the
lowest decile of the relative risk score based on all risk factors
except smoking, or based on BMI, OC use and HT use,
predicted EC incidence rates were only slightly higher than
those observed in India (Fig. 1). Notably, long duration of OC
use in the lowest decile of risk score was particularly influen-
tial. After excluding OC use, predicted incidence rates for
women in the lowest decile of the relative risk scores were
substantially higher than the corresponding models including
OC use. Across the 5-year age categories, the incidence rates
from the prediction model closely matched those observed in
EPIC and predicted for Europe (EU28; Supporting Informa-
tion Fig. S2) and the India (Chennai) data from Globocan
2018 are in line with the India country-wide summary esti-
mates and the low HDI estimates from Globocan 2012 (age-
specific data not available in Globocan 2018).
Discussion
Modeling changes in exposure to high BMI and HT use, as well
as to menstrual and reproductive factors, resulted in modest
reductions in predicted EC incidence rates in the EPIC cohort
study population. This study predicted ~30% lower EC incidence
when the study population was modeled as both having rela-
tively low BMI (≤23 kg/m2) and as never HT users, a combina-
tion of risk factors observed in 27% of the study population.
Modest changes in the predicted incidence (≤11% reductions)
were observed with modeled changes in ages at menarche and
menopause, and age at first term pregnancy. Predicted incidence
was 50% lower in models evaluating a low-risk profile with BMI
≤23 kg/m2, never HT use, menarche at age 13 or older and 3 or
more children, or 58% lower when additionally including age at
first pregnancy ≥25 and age at menopause ≤48 years. These pro-
files as modeled are modified toward risk factor patterns
observed in India in recent decades with data from India’s family
health surveys indicating a fertility rate of 2.9 children per
woman and a low prevalence of BMI≥25 kg/m2 [Ref 12]
(National Family Health Survey [NFHS]-2, 1998–1999; ever-
married women aged 15–49),12 and national surveys reporting
mean age at menarche of 14 (women born prior to 1955–1964)13
and mean age at menopause 47.5 years (birth cohort not speci-
fied).14 However, in our study population, the predicted ASR with
these lower-risk profiles (5.8 per 100,000 py and 4.8 per 100,000
py, respectively) were still >2.5-fold higher than rates observed in
India (1.9 per 100,000 in 2018), and these combinations of risk
factors were observed in small proportions of EPIC participants
(4 and 0.2%, respectively). We selected India as a representative
lower-risk country, given relatively high-quality registry data
(i.e., incidence rates from local/regional registries).15
Longer duration of OC use had a strong influence in decreas-
ing predicted EC incidence in our study population, as illustrated
by the risk patterns observed when classifying women in deciles
of multivariable relative risk score based different sets of modifi-
able and nonmodifiable risk factors, and both including and
excluding OC use. When the deciles were defined using a
multivariable risk score including OC use, the lowest risk decile
(i.e., 10%) of the cohort had predicted EC risk similar to that
observed in a low-risk country such as India, or in countries
classified as “low” on the human development index. More mod-
erate reductions in predicted incidence rates were observed in
models in which exposure to OC use was not modified. Oral
contraceptive use is less frequent in India (8.4% reported ever
use, married women ages 18–49 years, 1989–1999 NFHS-2),12
than in our population (ever use: 57%). Thus, while we identified
a subgroup of our study population with low EC risk comparable
to a low-risk country, the relatively low risks observed in these
two populations are due to different constellations of risk factors.
BMI, HT use and OC use were the three potentially modi-
fiable risk factors we evaluated toward understanding the EC
prevention potential with lower levels of exposure to EC risk
factors. Higher adiposity is associated with an extensive array
of sequelae, and contemporary evidence on HT use suggests
limiting its use to shorter-term therapy, in the nearer-term
following the onset of menopause for alleviation of vasomotor
symptoms or in women at high risk for bone loss.16 Thus, the
findings from our study predicting almost a third fewer EC
cases in the EPIC cohort through avoiding excess body fat
and abstention from HT use are in agreement with more glob-
ally accepted recommendations for exposure to these risk fac-
tors. However, it should be noted that we evaluated the
prevention potential of maintaining a lower BMI in the cur-
rent study, but were unable to assess the relative impact of
weight change on EC risk. The strong protective effect
observed with longer durations of OC use is more compli-
cated to interpret in terms of prevention potential. While OC
use is inversely associated with cancers of the endometrium,2
ovary,17,18 and colorectum,19,20 this must be balanced against
higher risks of breast21,22 and cervical cancers,23 and the
increased risk of cerebrovascular events, together with the
consideration of the contraceptive method(s) that best fit a
woman’s reproductive planning requirements.
While our study had important strengths, including the appli-
cation of a validated risk model to evaluate the theoretical reduc-
tion in EC risk due to lifestyle modification in a large cohort, the
results of our study must be considered in the context of several
limitations. First, exposure data were available only from the
baseline questionnaire, and we were unable to account for
changes in women’s exposure profiles during prospective follow-
up (e.g., women who had further pregnancies, or initiated HT
use), and data on HT formulation were not available. This would
result in a nondifferential misclassification of the evaluated expo-
sures, and attenuated associations. Furthermore, we modeled EC
as a composite outcome given limited data on histologic subtype.
Second, the oldest women in the EPIC cohort were born in the
late 1920s, and the OC pill was introduced in the 1960s. Thus,
the oldest EPIC participants had lower likelihood of exposure to
OCs, and would have been exposed for shorter durations, rela-
tive to women younger at recruitment. Furthermore, a birth-
cohort effect may be evident for other EC risk factors given
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trends toward younger age at menarche and older age at meno-
pause, and differences in HT prescribing patterns in recent
decades. Our results should be considered in the context of these
secular trends in prevalence of exposure to these EC risk factors.
It should also be noted that our modeled risk profiles (e.g., all
women BMI ≤23 kg/m2) are optimistic assumptions, and so may
present the upper bound of risk reduction. Finally, we compared
predicted EC incidence rates in our cohort across countries and
subgroups (e.g., “low HDI”) on the basis of modeled changes in
risk factor distributions, and without considering the constella-
tion of societal or infrastructure or healthcare-related factors
which also impact health outcomes.
Using a relative risk score including BMI, and HT and OC
use, approximately 10% of our study population had EC risk
similar to low-risk countries. Taken together, the results of
our study show that while a subset of our population had
lower EC risk, on par with lower-risk countries, we have not
fully identified natural risk factors accounting for the higher
EC risk in Europe. Avoidance of overweight and HT use were
identified as factors that can be modified toward reducing EC
risk, and lower risk of EC is an additional benefit gained from
avoiding these exposures. Future studies should evaluate the
prevention potential of weight loss, which we were unable to
address in the current study. While relatively long duration of
OC use resulted in lower predicted EC incidence, further stud-
ies evaluating a breadth of risks and benefits (including but
not limited to effective contraception, but also longer-term
safety) associated with OC use are required, in particular,
those evaluating more contemporary formulations, to inform
populations for whom longer-term use may be warranted for
chemoprevention.
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